Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.49 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.44 |
| ▸ | WNT1 | P04628 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.43 |
| ▸ | PLAT | P00750 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL915389 | 0.86 | HTR4 (0.51) | SMYD3WNT1DYRK1ANUDT1HPGDS | |
| SCHEMBL915139 | 0.85 | HTR7 (0.46) | WNT1DYRK1ANUDT1HPGDSHTR4 | |
| SCHEMBL914725 | 0.84 | TLR9 (0.44) | WNT1DYRK1AHTR4 | |
| SCHEMBL914569 | 0.84 | TLR9 (0.44) | WNT1DYRK1ANUDT1HPGDS | |
| SCHEMBL2762287 | 0.84 | GPR119 (0.51) | HPGDSCCNCCDK8HASPINPARP1 | |
| SCHEMBL5823101 | 0.83 | BRD4 (0.38) | BRD4ATAD2PLATCHEK1 | |
| SCHEMBL915087 | 0.82 | RAB9A (0.45) | SMYD3WNT1DYRK1ANUDT1HTR4 | |
| SCHEMBL914581 | 0.81 | GSK3B (0.42) | WNT1DYRK1AHPGDS | |
| SCHEMBL916126 | 0.80 | GSK3B (0.42) | WNT1DYRK1AHPGDS | |
| SCHEMBL2761944 | 0.79 | TDO2 (0.50) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183366-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| US-20110015180-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-7858781-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2010-12-28 | — | — | US | disclosed |
| EP-1720859-B1 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20070155721-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2007-07-05 | — | — | US | disclosed |
| EP-1720859-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005077932-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015180-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | BRD4 3280/4885ATAD2 4521/4885SMYD3 3615/4885 |
| US-20070155721-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | BRD4 3253/4885ATAD2 4511/4885SMYD3 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.